MaaT Pharma Will Host Investor Information Meeting Following Presentation at ASH Conference of Additional Results…
MaaT PharmaDecember 1, 2021
Ce communiqué ne peut être publié, distribué ou diffusé, directement ou indirectement, aux Etats-Unis d’Amérique,…
MaaT PharmaNovember 16, 2021
Results from HERACLES trial in 24 patients with GI-predominant, steroid-resistant grade III-IV aGvHD and from…
MaaT PharmaNovember 9, 2021
Advertisement This announcement is not being made in and copies of it shall not be…
MaaT PharmaOctober 15, 2021
L’Alliance Promotion Microbiote présente les résultats de la première étude sur l’industrie du microbiote en…
MaaT PharmaOctober 11, 2021
This press release shall not be published, transmitted, or distributed directly or indirectly to the…
MaaT PharmaOctober 4, 2021
MaaT Pharma awarded non-dilutive funding of EURO 1.9 million for its “MEPA” project through the…
MaaT PharmaJuly 20, 2021
Independent Data Safety and Monitoring Board (DSMB) recommends continuing study as planned and initiating dosing…
MaaT PharmaJune 28, 2021
